Cardiovascular Research Advance Access originally published online on March 13, 2008
Cardiovascular Research 2008 78(2):201-202; doi:10.1093/cvr/cvn070
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org
Mechanisms of angiogenesis and remodelling of the microvasculature
Cardiovascular Research Center Inserm Lariboisiere Inserm U689, Université Paris 7 Hôpital Lariboisière, 41 Bd de la Chapelle, 75475 Paris Cedex 10, France
* Corresponding author. Tel: +33 153216702; fax: +33 142813128. E-mail address: jean-sebastien.silvestre@larib.inserm.fr
| The first 10% of the full text of this article appears below. |
The development of blood vessels is essential for organ growth in the embryo and repair of wounded tissue in the adult. However, an imbalance in this process contributes to the pathogenesis of a number of disorders including cancer that is now recognized as the result of not only uncontrolled malignant cell proliferation but also uncontrolled vessel growth. The existence of tumour-derived factors responsible for promoting new vessel growth was postulated over 70 years ago, and a few years later, it was proposed that tumour growth is crucially dependent on neovascular supply. In 1971, pioneering work by Judah Folkmann, who sadly passed away on 14 January 2008, suggested that inhibition of angiogenesis would be an effective strategy to treat human cancer, leading to the development of